Publications by authors named "Fangxia Zou"

Claim this Profile
S
Structure-guided rational design of dual-target CGRP antagonist/5HT1F agonist therapeutics for migraine.
Fangxia Zou, Yutong Mao, Chunmei Li, Wenyan Wang, Wenjing Zhang

Eur J Med Chem· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Highly Potent Neurokinin‑3 Receptor Inhibitor: Design, Synthesis, and Evaluation.
Shengmin Ji, Hui Wang, Hengwei Xu, Wenjing Zhang, Yifei Yang, Fangxia Zou

ACS Med Chem Lett· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer's Disease-Related Psychosis.
Jing Lu, Pengfei Yu, Yunjie Wang, Yusen Dai, Wenyan Wang, Fangxia Zou

J Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1.
Jing Lu, Hui Lei, Xinfa Bai, Wenyan Wang, Chunjiao Liu, Fangxia Zou

Bioorg Chem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of piperazinotriazoles. Discovery of a potent and orally bioavailable neurokinin-3 receptor inhibitor.
Liang Ye, Yifei Yang, Chunmei Li, Jianzhao Zhang, Wenyan Wang, Fangxia Zou

Eur J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist.
Fangxia Zou, Yao Wang, Dawei Yu, Chunjiao Liu, Jing Lu

Eur J Med Chem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT receptor antagonists/inverse agonists.
Mingxu Ma, Yifei Yang, Guangying Du, Yusen Dai, Xiaoyin Zhu, Fangxia Zou

Eur J Med Chem· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia.
Wenyan Wang, Guangying Du, Shilan Lin, Jing Liu, Huijie Yang, Fangxia Zou

Front Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
Yifei Yang, Dawei Yu, Xiaoyin Zhu, Guangying Du, Wenyan Wang, Fangxia Zou

Eur J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Xiao Chen, Fangxia Zou, Zhengping Hu, Guangying Du, Pengfei Yu

Toxicol Appl Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Qiuju Dong, Pengfei Yu, Liang Ye, Jianzhao Zhang, Hongbo Wang, Fangxia Zou

Sci Rep· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
Tianfang Ma, Fangxia Zou, Stefan Pusch, Yungen Xu, Andreas von Deimling

J Med Chem· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Fangxia Zou, Stefan Pusch, Jie Hua, Tianfang Ma, Lijun Yang

Bioorg Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Tianfang Ma, Fangxia Zou, Stefan Pusch, Lijun Yang, Qihua Zhu

Bioorg Med Chem· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis